The Guanine Nucleotide Exchange Factors Trio, Ect2, and Vav3 Mediate the Invasive Behavior of Glioblastoma

Malignant gliomas are characterized by their ability to invade normal brain tissue. We have previously shown that the small GTPase Rac1 plays a role in both migration and invasion in gliomas. Here, we aim to identify Rac-activating guanine nucleotide exchange factors (GEFs) that mediate glioblastoma...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of pathology Vol. 173; no. 6; pp. 1828 - 1838
Main Authors Salhia, Bodour, Tran, Nhan L, Chan, Amanda, Wolf, Amparo, Nakada, Mitsutoshi, Rutka, Fiona, Ennis, Matthew, McDonough, Wendy S, Berens, Michael E, Symons, Marc, Rutka, James T
Format Journal Article
LanguageEnglish
Published Bethesda, MD Elsevier Inc 01.12.2008
ASIP
American Society for Investigative Pathology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Malignant gliomas are characterized by their ability to invade normal brain tissue. We have previously shown that the small GTPase Rac1 plays a role in both migration and invasion in gliomas. Here, we aim to identify Rac-activating guanine nucleotide exchange factors (GEFs) that mediate glioblastoma invasiveness. Using a brain tumor expression database, we identified three GEFs, Trio, Ect2, and Vav3, that are expressed at higher levels in glioblastoma versus low-grade glioma. The expression of these GEFs is also associated with poor patient survival. Quantitative real-time polymerase chain reaction and immunohistochemical analyses on an independent set of tumors confirmed that these GEFs are overexpressed in glioblastoma as compared with either nonneoplastic brain or low-grade gliomas. In addition, depletion of Trio, Ect2, and Vav3 by siRNA oligonucleotides suppresses glioblastoma cell migration and invasion. Depletion of either Ect2 or Trio also reduces the rate of cell proliferation. These results suggest that targeting GEFs may present novel strategies for anti-invasive therapy for malignant gliomas.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9440
1525-2191
DOI:10.2353/ajpath.2008.080043